<DOC>
	<DOCNO>NCT01319240</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare bioavailability insulin degludec liraglutide , administer either combine separate administration .</brief_summary>
	<brief_title>Safety Tolerability Insulin Degludec/Liraglutide ( A3 ) Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) Body Mass Index ( BMI ) 20.0 27.0 kg/m^2 ( inclusive ) Body weight 75 kg 90 kg ( inclusive ) Fasting plasma glucose 6.1 mmol/L ( 110 mg/dL ) Known suspect hypersensitivity trial product relate product Previous participation trial . Participation define randomise Previous participation clinical trial involve investigational product within last 3 month dose trial Donation blood plasma past month excess 500 mL within 3 month precede screening ( trial start ) surgery trauma 500 mL blood loss within 3 month precede screen History presence cancer , clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrine , diabetes , haematological , dermatological , venereal , neurological , psychiatric disease major disorder might impact trial , judge Investigator ( Trial Physician ) Clinically significant abnormal haematology , biochemistry , lipid , urinalysis coagulation screening test , judge Investigator ( Trial Physician ) Known hepatitis know carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody , positive result test HIV ( human immunodeficiency virus ) antibodies antigen Family personal history MEN2 ( Multiple endocrine neoplasia syndrome type 2 ) familial medullary thyroid carcinoma ( FMTC ) History chronic pancreatitis idiopathic acute pancreatitis Supine blood pressure screening , rest 5 min , outside range 90140 mmHg systolic 5090 mmHg diastolic ( exclude whitecoat hypertension ; therefore , repeat measurement second screen visit show value within range , subject include trial ) rest heart rate outside range 4090 bpm Clinically significant abnormal ECG ( Electrocardiogram ) screening ( trial start ) Significant history alcoholism drug/chemical abuse , positive result urine drug screen alcohol breath test , consume 21 unit alcohol per week ( one unit alcohol equal 250 mL beer lager , one glass wine , 20 mL spirit ) Smoking 5 cigarette , equivalent , per day unable refrain smoking inhouse period Mental incapacity language barrier preclude adequate understanding cooperation , unwillingness participate trial subject opinion Investigator ( trial physician ) participate trial Use prescription nonprescription medication , except paracetamol , acetylsalicylic acid , vitamin ( include megadose vitamin therapy , judge Investigator ( trial physician ) ) within 2 week trial Any condition would interfere trial participation evaluation result , judge Investigator ( trial physician ) Subjects history deep leg vein thrombosis frequent appearance deep leg vein thrombosis 1st degree relative judge Investigator ( trial physician ) Males sexually active surgically sterilise , whose partner use adequate contraceptive method ( adequate contraceptive measure require local law practice ) Baseline ( screen ) calcitonin level equal 50 ng/L Suffer life threaten disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>